Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2007

View Archived Issues

Novel treatment options for cancer covered in recent patent literature

Low daily doses of rimonabant reduce responses to cannabis

Phase III study results support the use of desvenlafaxine in major depressive disorder

New sodium channel SCN4A mutation underlying cold-induced myotonia identified / News in Context

Vertex reports third quarter 2007 results

New human TFF upregulators discovered at Otsuka

Amorfix discovers misfolded superoxide dismutase 1 protein in Alzheimer's disease

Merck Serono begins phase III clinical trial of safinamide in Parkinson's disease

Zogenix enters U.S. license agreement with Elan for late-stage, controlled-release opioid

Kissei patents novel agents for the treatment of gout

Sosei receives approval to initiate phase III trials of AD-923 in Europe

S*BIO initiates clinical development of SB-1317 as a therapy for acute leukemias

BioMarin files IND with FDA for PEG-PAL for the treatment of phenylketonuria

Abbott presents positive results from SPIRIT clinical trials of Xience

Geron initiates phase I/II clinical trial of GRN-163L in multiple myeloma

In vivo activity of novel agent for transplant rejection profiled at AstraZeneca

Astellas Pharma to acquire Agensys

7TM Pharma reports positive results from phase I/II clinical study of obinepitide for obesity

Antares and Population Council report positive results from phase I trial of contraceptive gel

Indevus reports positive results from phase II trial of octreotide implant for acromegaly

Ardea reports further positive results from the phase I MAD study of RDEA-806

GlaxoSmithKline presents third quarter 2007 results

Antidepressant treatment prolongs life in C. elegans

Pipex files NDA in U.S. for Coprexa in Wilson's disease

Health Canada accepts Santhera's new drug submission for SNT-MC17

Janssen granted approval for Prezista 300 mg tablet for HIV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...